The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 23, 2014
Filed:
Jul. 28, 2009
Markus Landthaler, Berlin, DE;
Manuel Ascano, Jr., New YorK, NY (US);
Markus Hafner, New York, NY (US);
Thomas Tuschl, Brooklyn, NY (US);
Mohsen Khorshid, Basel, CH;
Lukas Burger, Basel, CH;
Mihaela Zavolan, Binningen, CH;
Markus Landthaler, Berlin, DE;
Manuel Ascano, Jr., New YorK, NY (US);
Markus Hafner, New York, NY (US);
Thomas Tuschl, Brooklyn, NY (US);
Mohsen Khorshid, Basel, CH;
Lukas Burger, Basel, CH;
Mihaela Zavolan, Binningen, CH;
The Rockefeller University, New York, NY (US);
Abstract
The present invention relates to a method for identifying a binding site on an RNA transcript, wherein the binding site binds to one or more binding moieties. The method includes, among other things, introducing a photoreactive nucleoside into living cells wherein the living cells incorporate the photoreactive nucleoside into RNA transcripts during transcription thereby producing modified RNA transcripts; reverse transcribing the RNA of isolated cross-linked segments thereby generating cDNA transcripts with one mutation wherein the photoreactive nucleoside is transcribed to a mismatched deoxynucleoside; amplifying the cDNA transcripts thereby generating amplicons; and analyzing the sequences of the amplicons aligned against the reference sequence so as to identify the binding site, wherein the sequences of each amplicon having a mutation resulting from the introduction of the photoreactive nucleoside is considered to be a valid amplicon comprising at least a portion of a binding site on the RNA transcript.